Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2003

de vos tot Nederveen Cappel Wouter H, Offerhaus G Johan A, van Puijenbroek Marjo, Caspers Eric, Gruis Nelleke A, De Snoo Femke A, Lamers Cornelis B H W, Griffioen Gerrit, Bergman Wilma, Vasen Hans F A, Morreau Hans

Abstract excerpt

PURPOSE: The purpose is to document the clinical, pathological, and genetic features of pancreatic carcinoma (PC) in carriers of a specific p16-Leiden mutation (a 19-bp deletion in exon 2 of the CDKN2A gene). EXPERIMENTAL DESIGN: Clinical data and paraffin embedded tissue were obtained from 12 patients of p16-Leiden-positive families with PC. Because of the known 19-bp germ-line deletion, we could specifically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Cyclin-Dependent Kinase Inhibitor p16

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclooxygenase 2

Share to Genes, p16

Share to Loss of Heterozygosity

Share to Prostaglandin-Endoperoxide Synthases

Share to Registries

Share to Smad4 Protein

Source

Identifiers

PMID: 14506146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).PMID 14506146Read ↗

Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.Semantic proximity Read ↗

Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers.Semantic proximity Read ↗

Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion ofp16 (p16-Leiden)Semantic proximity Read ↗

Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 p16LeidenSemantic proximity Read ↗

Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).Semantic proximity Read ↗

High Growth Rate of Pancreatic Ductal Adenocarcinoma in CDKN2A-p16-Leiden Mutation Carriers.Semantic proximity Read ↗

Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.Semantic proximity Read ↗

CDKN2A germline mutations in familial pancreatic cancer.Semantic proximity Read ↗

Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas.Semantic proximity Read ↗

Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas.Semantic proximity Read ↗

Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer.Semantic proximity Read ↗

Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.